0 -phosphatase-1) functions as a negative regulator of immune responses by hydrolyzing phosphatidylinositol-3,4,5-triphosphate generated by phosphoinositide-3 (PI 3)-kinase activity. As a result, SHIP-1 deficiency in mice results in myeloproliferation and Bcell lymphoma. On the other hand, SHIP-1-deficient mice have a reduced T-cell population, but the underlying mechanisms are unknown. In this work, we hypothesized that SHIP-1 plays antiapoptotic functions in T cells upon stimulation of the death receptor CD95/APO-1/Fas. Using primary T cells from SHIP-1 À/À mice and T leukemic cell lines, we report that SHIP-1 is a potent inhibitor of CD95-induced death. We observed that a small fraction of the SHIP-1 pool is localized to the endoplasmic reticulum (ER), in which it promotes CD95 glycosylation. This post-translational modification requires an intact SH2 domain of SHIP-1, but is independent of its phosphatase activity. The glycosylated CD95 fails to oligomerize upon stimulation, resulting in impaired death-inducing signaling complex (DISC) formation and downstream apoptotic cascade. These results uncover an unanticipated inhibitory function for SHIP-1 and emphasize the role of glycosylation in the regulation of CD95 signaling in T cells. This work may also provide a new basis for therapeutic strategies using compounds inducing apoptosis through the CD95 pathway on SHIP-1-negative leukemic T cells.
Introduction
T lymphocytes homeostasis is tightly regulated by CD95-mediated apoptosis. 1, 2 Triggering the CD95 pathway by CD95 ligand or agonist antibodies induces its oligomerization and the subsequent formation of the death-inducing signaling complex (DISC), having as main components oligomerized CD95, the adaptor protein Fas-associated with death domain (FADD) and pro-caspase-8 and -10. 3 The recruitment of pro-caspase-8 to the DISC leads to its dimerization-induced auto-proteolytic cleavage and subsequent activation. Activated caspase-8 allows the activation of downstream effectors caspase-3 and -7, which in turn cleave cellular substrates, such as poly ADP ribose polymerase (PARP), resulting in cellular changes defining apoptosis. 1 Depending on the cell model, two pathways of CD95 signaling have been described. 4 Type I cells (Hut78 and H9 T leukemic cells and SKW6.4 B lymphoblastoid cells) show high DISC formation upon CD95 stimulation, and activated caspase-8 directly activates caspase-3. In type II cells (Jurkat and CEM T leukemic cells), low DISC formation is observed and the apoptotic signal is amplified by the release of cytochrome c from the mitochondria through the cleavage of Bid. 5, 6 SH2 (Src homology 2)-containing inositol 5 0 -phosphatase-1 (SHIP-1) is a 145-kDa protein mainly expressed in hematopoietic cells. 7 SHIP-1 harbors a central phosphatase domain, an N-terminal SH2 domain as well as a C-terminal domain that includes NPXY phosphorylation sites and proline-rich sequences. The SH2 domain and NPXY sites mediate the binding of SHIP-1 with a series of consensus motifs or adapter proteins. 8 Through its inositol phosphatase activity, SHIP-1 antagonizes the phosphoinositide-3 (PI 3)-kinase pathway by hydrolyzing phosphatidylinositol 3,4,5-triphosphate into phosphatidylinositol 3,4-diphosphate, thereby negatively regulating downstream survival pathways, such as Akt activation. 7 In support of this, germline deletion of SHIP-1 in mice or its downregulation by miR-155 that targets SHIP-1 results in myeloproliferation as well as B-cell lymphoma. [9] [10] [11] [12] For this reason, SHIP-1 is often considered as a tumor-suppressor protein. [13] [14] [15] Although several lines of evidence indicate its emerging importance, the role of SHIP-1 in T-cell fate is still unclear. 16, 17 In mice, SHIP-1 deficiency leads to a decrease in the T-cell population, particularly in the periphery. 9, 10, 18, 19 Peripheral T cells from SHIP-1 À/À mice are also constitutively activated and behave similar to T Reg cells. [18] [19] [20] Given the phenotype of SHIP-1 À/À mice, we hypothesized that SHIP-1 could have different roles depending on the cell type. We postulate that unlike its well-known pro-apoptotic activity in myeloid and B cells, SHIP-1 has an anti-apoptotic function in T cells. In this study, we report for the first time that SHIP-1 negatively regulates the CD95 signaling pathway in primary mouse T lymphocytes and in various human T leukemic cell lines. We observed that SHIP-1 localizes to the endoplasmic reticulum (ER), in which it increases the presence of highmolecular-weight forms of CD95 due to glycosylation. Evidence is provided to implicate SHIP-1 docking properties in this mechanism. The glycosylated CD95 fails to oligomerize upon stimulation, resulting in impaired DISC formation and apoptotic cascade.
Materials and methods

Murine T lymphocytes isolation and cell culture
Cell suspensions of spleen and lymph nodes from wild-type (WT) and SHIP-1 À/À mice were prepared and pooled. T cells were enriched by the magnetic activated cell sorting device (StemCell Technologies, Grenoble, France) using the mouse CD3 þ T-cell negative selection kit according to the manufacturer's instructions (StemCell Technologies). The purity of T cells was assessed by flow cytometry using an anti-CD3-phycoerythrin antibody (BD Pharmingen, Erembodegen, Belgium) and was estimated to be 490%. After isolation, primary murine T lymphocytes were maintained in RPMI medium containing 10% fetal bovine serum, 50 mM 2-mercaptoethanol, 1% L-glutamine, 25 mM HEPES, 50 mg/ml gentamycin and 50 U/ml interleukin-2. Jurkat, CEM and HuT78 T leukemic cells were cultured as previously described. 21 
Antibodies and reagents
Antibodies anti-SHIP-1 (clone P1C1) and anti-CD95 (clone C-20) were from Tebu Bio (Santa Cruz, CA, USA). Anti-actin was purchased from Sigma (Bornem, Belgium) and anti-CD2 from Serotec (Dü sseldorf, Germany). Anti-Akt and anti-P-Akt (T308) were from Cell Signaling (Beverly, MA, USA). Anti-PARP was purchased from BD Pharmingen. Anti-caspase-8 (clone C-15), anti-caspase-3, monoclonal anti-APO-1-3, soluble recombinant human CD95 ligand (SuperFas Ligand) and soluble recombinant human TRAIL ligand (SuperKiller TRAIL) were from Alexis Biochemicals (Zandhoven, Belgium). The monoclonal anti-CD95 antibody (clone 7C11) was from Beckman Coulter (Suarlée, Belgium). Tetracycline and camptothecin were purchased from Sigma. Biotinylated lectins were purchased from Vector Laboratories (Peterborough, UK). Agarose-linked streptavidin were obtained from Sigma. Glycoprotein Deglycosylation Kit (Cat. no. 362280) and benzyl-2-acetamido-2-deoxya-D-galactopyranoside (b-GalNAc, Cat. No. 200100) were from Calbiochem (La Jolla, CA, USA).
Lentiviral vectors and transduction protocol
Myc-tagged SHIP-1 WT, R41G (SH2 mutant) and D672A (catalytic mutant) expression vectors were previously described. 22 SHIP-1 coding sequence was subcloned in the BamHI/XhoI sites of the TRIPDU3-EF1a lentiviral vector. 23 Vector particles production and Jurkat cells infection were performed as previously described. 23 siRNA electroporation 1 Â 10 7 cells were incubated with 300 nM of SHIP-1 siRNA duplex (5 0 -GCUAAGUGCUUUACGAACA-3 0 , Applied Biosystems) 24 or 300 nM of control firefly luciferase siRNA (ref. AM4627, Applied Biosystems, Lennik, Belgium) for 10 min before electroporation (25 ms, 293 V) with a Bio-Rad gene pulser (Bio-Rad Laboratories, Eke-Nazareth, Belgium). The cells were then incubated for 20 min at room temperature and then maintained in Iscove's modified Dulbecco's medium (Fisher Bioblock, Tournai, Belgium) complemented with 20% fetal bovine serum.
CD95 stimulation
Jurkat, CEM and HuT78 T leukemic cells were treated with anti-CD95 antibodies (clone 7C11, Beckman Coulter or APO-1-3, Alexis) or SuperFas Ligand (Alexis) at concentration and times indicated. Primary murine T cells were activated by costimulation with anti-CD3/CD28-coated beads (Dynabeads, Fisher Bioblock, Tournai, Belgium) for 18 h before stimulation with SuperFas Ligand at concentration and time indicated.
DISC analysis
Cells (1 Â 10 8 ) were treated with 1 mg/ml anti-APO-1-3 for the indicated times at 37 1C. The CD95 DISC was immunoprecipitated from protein lysates at 4 1C for 2 h with protein-A Sepharose beads. The immunoprecipitates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by western blotting.
CD95 surface expression
Cell surface staining for CD95 was performed using a one-step procedure with phycoerythrin-conjugated anti-human CD95 (clone DX2, BD-Pharmingen, Germany) or phycoerythrinconjugated mouse IgG1 as a control (BD-Pharmingen). Cells were analyzed using flow cytometry (FACScanto Becton Dickinson, San Diego, CA, USA).
Glycosidase treatment and inhibition of glycosylation
Enzymatic removal of glycans was performed on cell lysates with a glycoprotein deglycosylation kit from Calbiochem (Cat. no. 362280) according to the manufacturer's instructions. Tunicamycin (Sigma) and benzyl-a-GalNAc (Calbiochem) were added to the cell culture for 48 h at final concentrations of 2 mg/ml and 4 mM, respectively. After 24 h of incubation, fresh inhibitor was added at the same final concentration.
Lectin pull-down assay
Lysates from Jurkat and Jurkat SHIP-1 cells were mixed with 40 mg of biotinylated lectins and incubated under rotation at 4 1C overnight. Lectin-glycoprotein complexes were then immunoprecipitated using Agarose-coupled streptavidin (Sigma).
Fractionation of subcellular organelles
Fractionation of subcellular organelles was performed essentially according to the Axis Shield NS11 (London, UK) protocol, allowing isolation of mitochondria, peroxisomes, ER and lysosomes. Isolation of the endoplasmic reticulum fraction was obtained by nonlinear Nycodenz density gradient ultracentrifugation.
Results
SHIP-1 protects primary T lymphocytes and T leukemic cells from CD95-induced apoptosis
Given the phenotype of SHIP-1 À/À mice, we hypothesized that SHIP-1 could exert an anti-apoptotic role in T lymphocytes. We isolated CD3 þ T cells from WT and SHIP-1 À/À mice and evaluated their ability to undergo apoptosis after activation, a prerequisite for their sensitivity to CD95-L, the major ligand regulating T-cell apoptosis in vivo.
1,2 Deficiency in SHIP-1 expression in KO mice was confirmed using western blotting SHIP-1 inhibits CD95-induced apoptosis in T lymphocytes E Charlier et al analysis on thymus extracts (Figure 1a) . AnnexinV/propidium iodide staining revealed that activated SHIP-1 À/À T cells show similar basal cell death compared with WT T cells (Figure 1b) . Upon CD95-L (SuperFas Ligand) treatment, cell death in SHIP-1 À/À T cells reached B90%, whereas only B60% of WT T cells died, suggesting that SHIP-1 indeed protects T lymphocytes from CD95-induced cytotoxicity (Figure 1b) . To explore the molecular mechanism involved, we used the Jurkat T leukemic cell line. Jurkat cells do not expressed SHIP-1 at the protein level 21, 25, 26 because of a bi-allelic null mutation and a frameshift deletion 27 and we restored SHIP-1 expression in these cells using lentiviral transduction method. As a negative control, Jurkat cells were transduced with an empty vector (hereafter referred as Jurkat Ev). SHIP-1 expression and catalytic activity were evaluated by western blotting using SHIP-1 and P-Akt (T308) antibodies, respectively. The constitutive P-Akt signal is elevated in Jurkat Ev, reflecting the absence of inositol phosphatase activity and the subsequent high basal level of phosphatidylinositol (3,4,5)-trisphosphate, the docking site for Akt 25, 26 ( Figure 1c ). In contrast, P-Akt was not detected in Jurkat expressing SHIP-1 exogenously (hereafter referred as Jurkat SHIP-1) or in the Jurkat JR cell line, a subclone that naturally expresses SHIP-1 21 ( Figure 1c ). To test whether SHIP-1 expression protects Jurkat cells from CD95-induced apoptosis, Jurkat Ev and Jurkat SHIP-1 cells were treated with CD95 antibodies (clones APO-1 and 7C11) or CD95-L for 24 h. As shown in Figure 1d , Jurkat SHIP-1 cells were significantly resistant to CD95-induced cell death when compared with Jurkat Ev. Similarly, we found that Jurkat SHIP-1 were also resistant to camptothecin and TRAILinduced apoptosis (Figure 1d) . Moreover, the analysis of pro-caspase-8, pro-caspase-3 and PARP cleavages in both cell lines treated with 7C11 Ab confirmed this result. In Jurkat Ev cells, pro-caspase-8 and -3 and PARP cleavage is observed at any time point of 7C11 Ab treatment, whereas the Jurkat SHIP-1 showed no processing of pro-caspase-8 and a delayed processing of pro-caspase-3 and PARP (Figure 1e ). Altogether, these data suggest that SHIP-1 negatively regulates CD95-mediated apoptosis in primary mouse T lymphocytes and in Jurkat leukemic cells. To further validate these results, we transiently knocked down the expression of SHIP-1 by RNA interference in various SHIP-1-positive T leukemic cell lines. SHIP-1 depleted Jurkat JR showed caspase-3 and PARP cleavages upon stimulation with 7C11 Ab, whereas no cleavage was observed in control cells (Figure 2a 
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The catalytic activity of SHIP-1 is not required for the protection against CD95-induced apoptosis
To determine whether the catalytic activity of SHIP-1 is involved in the protection against CD95-mediated apoptosis, we transduced Jurkat cells with a mutated form of SHIP-1 lacking phosphatase activity (SHIP-1 D672A). Western blotting analysis showed that SHIP-1 D672A was correctly expressed in Jurkat cells and was unable to reduce constitutive P-Akt (Figure 3a) . A slightly lower level of P-Akt is observed with the Jurkat D672A compared with the parental Jurkat cells, most probably because 
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E Charlier et al Figure 3b , expression of SHIP-1 D672A still protects Jurkat cells from CD95-induced apoptosis. Study of pro-caspase-8 and -3 and PARP cleavage confirmed these findings (Figure 3c ). To further confirm this result, we used Jurkat cells stably transfected with a CD2:SHIP-1 construct under the control of a Tet-Off expression system. 26 The resulting protein is a fusion of the rat CD2 transmembrane domain with the human SHIP-1 catalytic domain and thus shows constitutive inositol phosphatase activity at the membrane. 26 The Tetregulated expression of CD2:SHIP-1 as well as its catalytic activity were evaluated by western blotting analysis using anti-CD2 and P-Akt antibodies, respectively (Figure 3d ). The effect of Tet-regulated expression of the CD2:SHIP-1 chimeric protein on CD95-mediated cell death in Jurkat cells was next analyzed. We did not observe any significant difference in apoptotic cell death irrespective of whether the cells expressed or not the catalytic core of SHIP-1 (Figure 3e) . Altogether, these data suggest that the enzymatic activity of SHIP-1 is not involved in its antiapoptotic function upon CD95 stimulation in Jurkat T cells.
The SH2 domain of SHIP-1 is required for its anti-apoptotic activity upon CD95 induction
In addition to a catalytic domain, SHIP-1 encompasses a number of protein-protein interaction domains, including the SH2 sequence. 8 To analyze the involvement of this region in the anti-apoptotic function of SHIP-1, we generated the Jurkat SHIP-1 R41G cell line, which expresses a mutated form of SHIP-1 lacking functional SH2 domain but still able to inhibit P-Akt (Figure 3f) . Strikingly, we observed that expression of SHIP-1 R41G restored the sensitivity to 7C11 Ab-induced apoptosis to levels similar to those observed with parental Jurkat cells (Figure 3g ). This was supported by the pro-caspase-8 and -3 and PARP cleavage profiles (Figure 3h ). These data suggest that SHIP-1-negative regulation of CD95-mediated apoptosis involves the docking properties of SHIP-1 SH2 domain.
SHIP-1 does not affect CD95 membrane expression but increases the presence of high-molecular-weight forms of the receptor
We next wondered whether SHIP-1 could modulate the expression of CD95 on the cell surface by flow cytometry. A normal, and even higher, expression of CD95 at the surface of Jurkat SHIP-1 when compared with Jurkat Ev or Jurkat SHIP-1 R41G was observed (Figure 4a ), indicating that SHIP-1 does not inhibit the trafficking of CD95 to the plasma membrane. However, western blotting analysis revealed the presence of higher-molecular-weight forms of CD95 upon SHIP-1 expression in Jurkat cells (Figure 4b ). This electrophoretic mobility shift corresponds to approximately 10 kDa and is no more induced upon SHIP-1 R41G expression (Figure 4b ). Importantly, this CD95 shift was also detected in all the SHIP-1-positive leukemic cell lines tested in this study (Figure 4c ). These results suggest that SHIP-1 induces a sodium dodecyl sulfate-resistant posttranslational modification of CD95 in a SH2 domain-dependent manner. However, despite having a higher molecular weight, the modified CD95 routed normally to the cell surface.
SHIP-1 promotes CD95 glycosylation
It has been shown that CD95 is a glycoprotein whose molecular weight can vary depending on the level of N-or O-linked carbohydrate residues added. [28] [29] [30] We therefore studied the effect of oligosaccharide chain removal on CD95 molecular weight in Jurkat Ev and Jurkat SHIP-1. We used a set of enzymes that remove all N-and O-linked oligosaccharides from glycoproteins and observed a decrease in CD95 molecular weight to B35 kDa in both Jurkat Ev and SHIP-1, which corresponds to the predicted size of CD95 without any modification 29 ( Figure 5a ). This result indicates that CD95 is basally glycosylated in Jurkat Ev and that the CD95 shift induced by SHIP-1 expression corresponds to an additional carbohydrate moiety. We then separately analyzed N-and O-glycosylation of CD95 from both cell lines, using pharmacological inhibitors of either N-glycosylation (that is, tunicamycin) or O-glycosylation (that is, benzyl-GalNAc, which competitively inhibits the extension of the Tn antigen (GalNAc-Ser/Thr) to more complex O-glycans) (Supplementary Materials and Methods). As shown in Supplementary Figure 1a , addition of tunicamycin to Jurkat Ev cells generated the shortest form of CD95 (B35 kDa), whereas in Jurkat SHIP-1 cells, the use of tunicamycin made CD95 detection size only felt to the B40 kDa form observed in nontreated Jurkat Ev cells. However, addition of benzyl-GalNAc provoked a partial decrease in CD95 molecular weight only in Jurkat SHIP-1 cells (Supplementary Figure 1b) . Altogether, these results suggest that CD95 from Jurkat Ev is basally Nglycosylated, and that the CD95 shift induced by SHIP-1 corresponds to additional O-glycans. However, from these western blotting experiments, we cannot rule out firmly that minor changes in N-glycosylation also occurred. To better evaluate the differences in CD95 glycans content, we performed a lectin pull-down assay. CD95 from both Jurkat and Jurkat SHIP-1 cells interacted with SNA (Sambucus nigra) and RCA 120 (Ricinus communis) lectins, indicating the presence of, respectively, sialic acid and galactose residues in both cell lines (Figure 5b ). However, CD95 from Jurkat SHIP-1 also reacted with other lectins, in particular UEA (Ulex europaeus; fucose) or WGA (Wheat Germ Agglutinin; N-acetylglucosamine), indicating a more complex glycosylation pattern than in parental Jurkat cells (Figure 5b) . A recapitulative table is shown in Figure 5c . Obviously, structural characterization of CD95 glycosylation would be the best mean to rigorously compare the differences between CD95 from Jurkat Ev versus Jurkat SHIP-1, but this is a very challenging task that is outside the scope of this study. It was, nevertheless, possible to gain some insight into the glycosylation changes occurring upon SHIP-1 expression by using mass spectrometric methodologies to fingerprint the Nand O-glycans present in Jurkat Ev, Jurkat SHIP-1 and CEM cells (Supplementary Material and Methods). All three cell types expressed the same repertoire of N-glycans, although with some minor abundance differences (Supplementary Table 1 and data not shown). In contrast, a dramatic difference was observed in O-glycosylation of Jurkat cells with and without SHIP-1. Thus, in accordance with the known absence of a functional core 1 synthase in Jurkat cells, the Tn antigen (GalNAc) was the only significant glycan observed in these cells (Supplementary  Table 2) . 31 In contrast, this antigen was not detectable in Jurkat SHIP-1 and CEM cells. Instead, these cells expressed a mixture of core type 1 and core type 2 O-glycans that are typical of leukocytes. 32 Together, these results show that the major effect of SHIP-1 expression on Jurkat glycosylation is the restitution of the normal O-glycosylation pathway that stops at Tn (GalNAc-Ser/Thr) synthesis in WT Jurkat cells. Further evidence that the core 1 synthase is active in the Jurkat cells expressing SHIP-1 was obtained by treating the CD95 samples with sialidase and O-glycanase. This combination of enzymes removes intact core type 1 sequences but not the Tn antigen.
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A substantial shift in molecular weight of Jurkat SHIP-1 CD95 was observed using these enzymes (Supplementary Figure 2) , confirming the presence of sialylated core type 1 glycans in this sample.
Inhibition of N-, but not O-glycosylation, restores CD95 sensitivity in Jurkat SHIP-1
We next analyzed whether inhibition of N-or O-glycosylation could sensitize Jurkat SHIP-1 to CD95-induced cell death. Pre-treatment of Jurkat SHIP-1 with the N-glycosylation inhibitor tunicamycin significantly increased 7C11 Ab-induced cell death when compared with non pre-treated cells (Figure 6a ). PARP cleavage detection by western blotting confirmed this result (Figure 6b ). In contrast, pre-treatment of Jurkat SHIP-1 with benzyl-GalNAc, an inhibitor of O-glycosylation, did not modify 7C11 Ab-induced cell death compared with non pre-treated cells (Figure 6a ). However, sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that benzyl-GalNAc treatment reduced the molecular weight of CD95 to an intermediate position between that of Jurkat Ev CD95 and Jurkat SHIP-1 CD95, suggesting that only partial inhibition of O-glycan biosynthesis had occurred (Supplementary Figure 1b) . Therefore, no firm conclusions concerning the importance of O-glycosylation in SHIP-1-negative regulation of CD95-induced apoptosis could be drawn from this experiment. On the other hand, the tunicamycin experiment suggested that the N-glycosylation status of CD95 is important for apoptotic activity. Whether the N-linked oligosaccharides themselves are directly involved, or whether their absence in the tunicamycin experiment results in altered O-glycosylation leading to the observed effects, remains to be established.
SHIP-1 is localized to the ER
To understand the mechanism involved in SHIP-1-induced CD95 glycosylation, SHIP-1 subcellular localization was analyzed. Nascent polypeptide chains become initially N-glycosylated with a mannose-rich branched oligosaccharide in the ER, 33 and it was reported that some phosphatases like PTP-1B are localized to ER membranes, 34 in which they control glycosylation state of receptor tyrosine kinases. 35 A biochemical analysis of subcellular fractionation performed on Jurkat SHIP-1 revealed that B15% of the SHIP-1 pool was detected in the 
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fraction of membrane/organelle that coincides with the ER marker Grp78 (Figure 7a) . Similarly, a nonlinear Nycodenz density gradient ultracentrifugation performed on the membrane/organelle fraction revealed that SHIP-1 and CD95 are present in fractions corresponding to the ER (Figure 7b , fractions 5-8). Collectively, these data suggest that SHIP-1 is localized to the ER together with CD95.
Glycosylated CD95 fails to oligomerize and to recruit the DISC upon stimulation
To further establish a relationship between SHIP-1 expression and the apoptosis inhibition, we explored the effect of SHIP-1-induced CD95 glycosylation on CD95 oligomerization and DISC formation, which are two early events required for efficient downstream signaling. 1 Jurkat Ev and Jurkat SHIP-1 cells were stimulated with the APO-1 antibody. Anti-APO-1 immunoprecipitations followed by anti-CD95 western blotting were carried out. Stimulation of Jurkat Ev cells induced the presence of sodium dodecyl sulfate and 2-mercaptoethanolresistant CD95 aggregates of high molecular weight corresponding to oligomerized forms of CD95, 36 whereas Jurkat SHIP-1 cells showed much less CD95 aggregates upon stimulation (Figure 8a ). We also analyzed DISC formation by blotting caspase-8 and FADD after CD95 immunoprecipitations. We observed that FADD and caspase-8 were strongly recruited to CD95 at 5-15 min after stimulation of Jurkat Ev cells (Figure 8a ). p18 cleavage product of caspase-8 was also detected, reflecting caspase-8 activation. 37 In contrast, FADD and caspase-8 were only slightly recruited in Jurkat SHIP-1 cells, and no p18 was detected at these time points (Figure 8a) . Interestingly, CD95 oligomerization and DISC formation were nearly completely restored in Jurkat expressing SHIP-1 R41G (Figure 8a ). It is noteworthy that no SHIP-1 was detected at the DISC (Figure 8a ). Corresponding lysates before immunoprecipitation are shown in Figure 8b . On the basis of our data, we conclude that 
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E Charlier et al hyperglycosylation of CD95 prevents its oligomerization and subsequent DISC formation upon stimulation.
Discussion
Lymphopenia observed in SHIP-1-deficient mice suggests that SHIP-1 is involved in the survival of T lymphocytes, which is in contradiction with the well-established inhibitory function of this phosphatase in the myeloid lineage. 7 CD95 is the prototypic regulator of T-cell homeostasis that induces T-cell apoptosis, thereby terminating the immune response. 1, 2 In this study we report for the first time that SHIP-1 protects both primary T lymphocytes and type I and II T leukemic cell lines against CD95-induced apoptosis. Interestingly, we have shown that SHIP-1 anti-apoptotic role is independent of its inositol phosphatase activity, but requires an intact SH2 domain. This implies that in T cells, despite the fact that SHIP-1 can downregulate P-Akt, its prominent role is not related to its phosphatase activity, but relies on the anti-apoptotic activity of its SH2 domain. In contrast, lymphocytes from phosphatase and tensin homolog (PTEN) þ /À mice are unresponsive to CD95-mediated apoptosis, and these mice develop lymphoproliferative disorders. 38 T-cell-specific loss of phosphatase and tensin homolog gives rise to the same phenotype. 39 This suggests that phosphatase and tensin homolog and SHIP-1 inositol phosphatases have non-redundant roles in T lymphocyte apoptosis. The role of SHIP-1 in T lymphocyte biology is still poorly understood and debated. SHIP-1 deficiency in mice not only leads to myeloproliferation and B-cell lymphoma, but also to a decrease in the percentage of circulating lymphocytes, particularly in the periphery. 9, 10, 18, 19 Peripheral T cells from SHIP-1 À/À mice are also constitutively activated and behave similar to T Reg cells. [18] [19] [20] However, T-cell-specific deletion of SHIP-1 did not lead to altered T-cell number, activation or emergence of T Reg cells, but instead revealed a role for SHIP-1 in the regulation of Th1/Th2 and cytotoxic responses. 40 It was proposed that the emergence of T Reg cells in mice bearing a germline mutation of SHIP-1 might be a consequence of the inflammatory environment in those mice rather than a T-cell defect as a result of SHIP-1 deletion. 40 Nevertheless, the influence of SHIP-1 deficiency on CD95-induced apoptosis was never examined upon T-cell activation, which is a condition necessary for their sensitivity to CD95-mediated cell death, likely to occur in the inflammatory environment present in SHIP-1 À/À mice. Our results suggest that in the course of an immune/inflammatory response, SHIP-1 is a key negative regulator of CD95-induced T-cell death. On the other hand, it is noteworthy that freshly isolated T Reg are highly sensitive toward CD95-induced apoptosis, similar to T cells from SHIP-1 À/À mice, thereby reinforcing the existence of a potential link between SHIP-1, T Reg cells development and apoptosis sensitivity. 41 In this work, we also showed for the first time the association of SHIP-1 with the ER. Several protein phosphatases, including PTP-1B and SHP-1, were also found to be localized in the ER or to be enriched in a perinuclear compartment, in which they regulate receptor maturation or trafficking. 35 Our observation of SHIP-1 localization to the ER opens new avenues of research about its function in cellular mechanisms probably unrelated to its control of PI 3-kinase signaling. Notably, we found that SHIP-1 promotes CD95 glycosylation through the involvement of its SH2 domain. Remarkably, SHIP-1 Jurkat cells express a similar repertoire of O-glycans to those found in CEM cells, which express SHIP-1 naturally. These glycans are mono-and disialylated core type 1 and core type 2 O-glycans (Supplementary Table 2 ). In WT Jurkat cells, O-glycosylation is restricted to the formation of the Tn antigen (GalNAc-Ser/Thr). This is because they lack the active T synthase that is required for the addition of galactose to the Tn antigen to form the core type 1 sequence (Galb1-3GalNAc-Ser/Thr), which is the precursor for all O-glycans in normal leukocytes. T synthase, which resides in the Golgi apparatus, requires a chaperone called Cosmc for correct folding in the ER. Because Jurkat cells lack functional Cosmc, due to a mutation that introduces a stop codon near the middle of its gene, their T synthase is incorrectly folded in the ER and is routed to the proteasome for degradation. 31, 42 Our data indicate that SHIP-1 expression rescues Cosmc function through a yet-unknown mechanism, perhaps through docking with the cytoplasmic domain of T synthase and/or the truncated Cosmc. Previous cloning of CD95 has suggested the protein to be glycosylated, but structural information is sparse and the influence of glycosylation on CD95 signaling is poorly understood. In this study we report that Jurkat SHIP-1 CD95 carrying sialylated complex O-glycans, which are absent in WT Jurkat CD95, was routed normally to the cell surface. However, it failed to oligomerize upon stimulation, resulting in an impaired apoptotic signaling cascade.
Several studies suggest that SHIP-1 inactivation can participate in the leukemogenic process in T cells. Indeed, recent findings by Lo et al. 27 report near-universal inactivation of SHIP- The individual fractions from the top to the bottom were subjected to western blotting analysis, using specific antibodies directed against SHIP-1, Grp78 and CD95.
SHIP-1 inhibits CD95-induced apoptosis in T lymphocytes E Charlier et al 1 in childhood T-cell acute lymphoblastic leukemia (T-ALL). It has been postulated that this inactivation could have a role in the deregulation of Akt pathway and tumorigenesis in T-cell acute lymphoblastic leukemia, probably in conjunction with phosphatase and tensin homolog inactivation. Accordingly, restoration of SHIP-1 expression in Jurkat T leukemic cells downregulates constitutively activated PI 3-K and AKT signaling pathway and leads to an increased transit time through the G1 phase of the cell cycle, thereby downregulating the proliferation of these cells. 43, 44 We now propose that SHIP-1, through its SH2 domain, also acts as a potent regulator of T-cell homeostasis by inhibiting CD95-mediated cell death. Taken together, these results may provide a new basis for therapeutic interventions using compounds engaging the CD95 pathway on SHIP-1-negative leukemic T cells. Our data also raise serious concerns about possible complications associated with SHIP-1 gene transfer for the treatment of T-cell acute lymphoblastic leukemia. 
